| 16.49 0.14 (0.86%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.04 | 1-year : | 23.41 |
| Resists | First : | 17.16 | Second : | 20.04 |
| Pivot price | 15.23  |
|||
| Supports | First : | 13.92 | Second : | 11.92 |
| MAs | MA(5) : | 16.61 |
MA(20) : | 14.58 |
| MA(100) : | 12.17 |
MA(250) : | 15.32  |
|
| MACD | MACD : | 1 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 86.9 |
D(3) : | 90.1 |
| RSI | RSI(14): 66.2 |
|||
| 52-week | High : | 35.68 | Low : | 6.36 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DYN ] has closed below upper band by 27.1%. Bollinger Bands are 67.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 16.86 - 16.96 | 16.96 - 17.06 |
| Low: | 15.82 - 15.92 | 15.92 - 16.03 |
| Close: | 16.15 - 16.33 | 16.33 - 16.53 |
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Tue, 21 Oct 2025
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Unveiling a Potential 102% Upside in the Biotech Sector - DirectorsTalk Interviews
Tue, 14 Oct 2025
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A 145% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Fri, 10 Oct 2025
Dyne Therapeutics (DYN) Sees Downgrade by Oppenheimer | DYN Stoc - GuruFocus
Fri, 10 Oct 2025
Dyne Therapeutics (DYN) Is Up 17.0% After Positive One-Year ACHIEVE Trial Data for Z-Basivarsen – Has The Bull Case Changed? - Yahoo Finance
Tue, 07 Oct 2025
Dyne Therapeutics Inc. (DYN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Mon, 06 Oct 2025
Dyne Therapeutics Reports 1-Year Functional Gains at 6.8 mg/kg | DYN Stock News - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 142 (M) |
| Shares Float | 123 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 94.6 (%) |
| Shares Short | 17,770 (K) |
| Shares Short P.Month | 16,040 (K) |
| EPS | -3.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.5 % |
| Return on Equity (ttm) | -61.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -360 (M) |
| Levered Free Cash Flow | -222 (M) |
| PE Ratio | -4.26 |
| PEG Ratio | 0 |
| Price to Book value | 3.3 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|